Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,655 across all filing types
Latest filing 2022-01-25 Board/Management Inform…
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
第三届监事会第五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a resolution announcement from the Supervisory Board (监事会) of Shenzhen BGI Genomics Co., Ltd. It details the meeting procedures, voting results, and approvals of various company matters such as related party transactions, donations, cash management, foreign exchange derivatives, and share repurchase plans. The document does not contain financial statements or detailed financial analysis but rather formal meeting resolutions and approvals. It is a formal announcement of board/management decisions rather than a full report or financial disclosure. Therefore, it fits best under the category of Board/Management Information (MANG). The document length is 3375 characters, which is consistent with a meeting resolution announcement rather than a full report.
2022-01-25 Chinese
关于召开2022年第一次临时股东大会的通知
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a detailed notice about convening the 2022 first extraordinary general meeting (临时股东大会) of Shenzhen BGI Genomics Co., Ltd. It includes information about the meeting date, voting procedures, proposals to be voted on, registration details, and attachments such as proxy forms and shareholder registration forms. There is no financial data, earnings, or management discussion. It is not a report but a formal announcement and invitation to shareholders to attend and vote at the meeting. This fits the category of a Proxy Solicitation & Information Statement (PSI), which provides materials sent to shareholders to inform and request votes for meetings.
2022-01-25 Chinese
中信证券股份有限公司关于深圳华大基因股份有限公司向深圳市猛犸公益基金会捐赠暨关联交易的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed opinion and verification report from CITIC Securities regarding a related-party transaction involving Shenzhen BGI Genomics Co., Ltd. donating funds and assets to the Shenzhen Mammoth Public Welfare Foundation. It includes descriptions of the transaction, related party relationships, board and supervisory committee approvals, independent directors' opinions, and the sponsor's verification opinion. The document is not a financial report, earnings release, or regulatory filing in the usual sense but rather a formal verification opinion on a specific related-party transaction. It does not fit categories like Annual Report, Interim Report, or Earnings Release. It is not a simple announcement or a proxy solicitation. The document is a formal audit or verification opinion related to a specific transaction, which aligns best with the Audit Report / Information (AR) category, as it involves verification and audit opinions on the transaction and compliance with regulations. The document length is 4397 characters, which is substantive and contains detailed content, not just an announcement or certification. Therefore, the best classification is AR with high confidence. Q1 2022
2022-01-25 Chinese
关于开展外汇衍生品交易业务的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Shenzhen BGI Genomics Co., Ltd. regarding the commencement of foreign exchange derivative trading business. It details the investment types, amounts, risk analysis, control measures, and approvals from the board and supervisory committee. The document includes the date of board approval and independent opinions but does not contain financial statements or detailed financial performance data. It is a regulatory announcement about a new business activity and risk management, not a financial report or earnings release. The document length is 4231 characters, which is relatively short and focused on disclosure of a specific business decision. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2022-01-25 Chinese
关于 2022年度日常关联交易预计的公告
Regulatory Filings Classification · 95% confidence The document is a detailed announcement from Shenzhen BGI Genomics Co., Ltd. regarding the expected daily related party transactions for the year 2022. It includes extensive data on transaction categories, amounts, related parties, and historical comparisons for 2021. The content focuses on the company's related party transactions, their approval processes, and compliance with Shenzhen Stock Exchange rules. There is no indication that this is a full annual report, audit report, earnings release, or other financial statement. Instead, it is a regulatory announcement about related party transactions, which is a common type of regulatory filing in Chinese markets. The document is lengthy (15,000 characters) and contains substantive data, but it is not a financial report per se. It is not a report publication announcement since it contains detailed data rather than just a notice of report availability. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2022-01-25 Chinese
中信证券股份有限公司关于深圳华大基因股份有限公司2022年度日常关联交易预计的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from CITIC Securities regarding the 2022 annual expected daily related party transactions of Shenzhen BGI Genomics Co., Ltd. It includes extensive financial data on transaction amounts, categories, and counterparties, as well as explanations of the approval process and actual transaction execution for 2021. The content focuses on related party transactions, their pricing principles, and compliance with regulatory requirements. It is not a general annual report, earnings release, or management discussion but a specialized audit or verification opinion on related party transactions for the year 2022. The document length is substantial (15,000 characters), and it contains detailed financial and operational data, not merely an announcement or certification. Therefore, it fits best under the category of Audit Report / Information (AR), which covers standalone audit reports and applied accounting principles related to specific regulatory or internal reviews, excluding full annual reports. FY 2022
2022-01-25 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.